IB Neuro's Quantitative Mapping Method Assesses Metastatic Tumors

Rhea-AI Summary

Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB:IQAIF), highlights a study published in the American Journal of Neuroradiology showing that its DSC-MRI technology effectively distinguishes between tumor and non-tumor tissues in metastatic brain tumors treated with stereotactic radiosurgery. This study, led by Dr. Michael Iv, demonstrates IB Neuro's superior imaging capability compared to traditional methods. With brain metastases expected to rise, the findings validate the development of IB Trax software, enhancing monitoring and accuracy for neuroradiologists.

Positive

• IB Neuro's DSC-MRI technology distinguishes tumor from non-tumor tissue in metastatic brain tumors, demonstrating superior performance compared to DCE imaging, ASL, and PET.
• The study's success underscores the reliability of IB Neuro's standardized relative cerebral blood volume (rCBV) measurement, enhancing diagnostic capabilities.
• The development of IB Trax, integrating quantitative Delta T1 and sRCBV maps, is expected to boost neuroradiologists' ability to monitor brain metastases.

Negative

• None.

Study Shows DSC MRI Perfusion Distinguishes Tumor from Non-Tumor Tissue

MILWAUKEE, WI / ACCESSWIRE / May 3, 2022 / Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB:IQAIF)(LSE:IQAI), notes a recent study published in the American Journal of Neuroradiology entitled: DSC Perfusion-Derived Fractional Tumor Burden and Relative CBV Differentiate Tumor Progression and Radiation Necrosis in Brain Metastases Treated with Stereotactic Radiosurgery.

The retrospective study, led by Dr. Michael Iv, MD, Clinical Associate Professor at Stanford University, used IB Software and other advanced imaging methods to evaluate metastatic brain tumors previously treated with a very precise form of radiation therapy called stereotactic radiosurgery. The goal was to determine which, if any, imaging technology could reliably distinguish between progressive tumor and radiation necrosis (non-tumor) tissue. The study concluded that IB Neuro's dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) perfusion-derived maps were able to make this distinction whereas the other methods to which it was compared could not. Those other methods included dynamic contrast enhanced (DCE) imaging, arterial spin labeling (ASL) which is an MRI technique that uses the body's own blood as a contrast agent to compute blood flow measurements, and positron emission tomography (PET) which can detect metabolic differences in tissue.

DSC-MRI is well established as the most robust and clinically adopted method for response assessment in high-grade (HG) primary brain tumors. Numerous studies have demonstrated the accuracy and reproducibility of IB Neuro's DSC platform and, specifically, its standardized measurement of relative cerebral blood volume (rCBV) to distinguish tumor from non-tumor tissue in HG tumors. This study is the first to replicate this method in metastatic brain tumors. The results are positive news for treatment teams who currently must rely on contrast-enhanced MRI to answer the basic question - is the enhancing region tumor, or is it an effect due to treatment?

Metastatic brain tumors are ten times more prevalent than primary brain tumors. This year in the US alone, it is expected that 220,000 people will be diagnosed with a metastatic brain cancer. Moreover, advances in treatment therapy are helping metastatic brain tumor patients live longer with improved quality of life. Thus, this number is expected to increase over time. Up to 50% of all cancers will eventually metastasize to the brain.

The study referred to IB's standardized rCBV (sRCBV) measurement. Standardization is an exclusive calibration technology that is built-in to IB Neuro. Fully automated, standardization translates the relative MRI image intensities to a fixed and consistent quantitative scale. This machine-learned technology is applied once for all scanner platforms, field strengths, and patients, and enables direct quantitative comparison between scans. It has been shown superior over other tissue normalization techniques; all of which require manual user input and are, therefore, less consistent and cannot be automated. The ability to obtain quantitative sRCBV values on a per-voxel basis differentiates IB Neuro from all other DSC-MRI platforms.

"This relevant and powerful study further validates our decision to develop IB Trax™. Incorporating our quantitative Delta T1 (patent-pending) and sRCBV maps will help neuroradiologists track and monitor brain metastases over time and potentially boost their accuracy and efficiency," said Trevor Brown, CEO and Chairman of IQ-AI, Ltd.

About IQ-AI Limited

IQ-AI Limited, (LON:IQAI)(OTCQB:IQAIF), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com

Safe Harbor Statement

This press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," or the negative of these words and/or similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. For example, statements about future revenues and the Company's ability to fund its operations and contractual obligations are forward looking and subject to risks. Several important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, the inability to raise capital to support the Company through its growth stage, the Company's inability to generate projected sales and trade relations between the United States and China. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Investor Relations Contact:
Michael Porter, President
Porter, LeVay & Rose, Inc.
Tel: 212-564-4700
mike@plrinvest.com

SOURCE: IQ AI Ltd.

View source version on accesswire.com:
https://www.accesswire.com/699922/IB-Neuros-Quantitative-Mapping-Method-Assesses-Metastatic-Tumors

FAQ

What did the study involving IQ-AI (IQAIF) reveal about DSC-MRI?

The study showed that DSC-MRI effectively distinguishes between tumor and non-tumor tissue in metastatic brain tumors.

Who led the study on DSC-MRI technology for IQ-AI (IQAIF)?

The study was led by Dr. Michael Iv, MD, Clinical Associate Professor at Stanford University.

How does IB Neuro's DSC-MRI compare to other imaging methods?

IB Neuro's DSC-MRI significantly outperformed DCE imaging, ASL, and PET in distinguishing tumor progression from radiation necrosis.

What is the significance of the study for metastatic brain tumors?

The study is crucial as metastatic brain tumors are more prevalent than primary brain tumors and demonstrate a rising diagnosis rate.

What innovation is IQ-AI (IQAIF) developing based on the study's findings?

IQ-AI is developing IB Trax, which incorporates quantitative mapping to enhance tracking of brain metastases.